Stem Cell Therapeutics Corp. Investor Update
September 27 2011 - 2:27PM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the
"Company") has posted an investor update on its corporate website -
StemCellThera.com. The update includes a letter to shareholders
together with a video condensed from the corporate update provided
at the annual meeting of shareholders of August 18, 2011.
The Company also wishes to announce a presentation at the World
Stem Cell Conference, Pasadena, CA, on Wednesday, October 5, 2011
at 1 PM entitled "Prolactin Stimulates Endogenous Stem Cell
Mediated Remyelination in Animal Models of Central Nervous System
Injury". The presentation shall be made by Dr Allen Davidoff, Chief
Scientific Officer of the Corporation'.
About Stem Cell Therapeutics Corp: Stem Cell Therapeutics Corp.
is a public biotechnology company principally developing for
commercialization drug-based therapies to treat central nervous
system diseases. SCT is a leader in the development of therapies
that utilize drugs to stimulate a patient's own resident stem
cells. The Company's programs aim to repair brain and nerve
function lost due to disease or injury. SCT's extensive patent
portfolio of owned and licensed intellectual property supports the
potential expansion into future clinical programs in numerous
neurological diseases such as stroke, traumatic brain injury,
multiple sclerosis, Huntington's disease, Alzheimer's disease, and
ALS.
Caution Regarding Forward-Looking Information:
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable
Canadian provincial securities legislation (collectively, the
"forward-looking statements"). These forward-looking statements
relate to, among other things, SCT's objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, and
can, in some cases, be identified by the use of words such as
"believe," "anticipate," "expect," "intend," "plan," "will," "may"
and other similar expressions. In addition, any statements that
refer to expectations, projections or other characterizations of
future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are applied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that
could cause actual results to differ materially from these
expectations include, among other things: uncertainties and risks
related to, the availability of capital, changes in capital
markets, uncertainties related to clinical trials and product
development, rapid technological change, uncertainties related to
forecasts, competition, potential product liability, unproven
markets for technologies in development, the cost and supply of raw
materials, management of growth, effects of payors' willingness to
pay for products, risks related to regulatory matters and risks
related to intellectual property matters. Additional information
about these factors and about the material factors or assumptions
underlying such forward-looking statements may be found in the body
of this news release, as well as under the heading "Risk Factors"
contained in SCT's 2010 annual information form. SCT cautions that
the foregoing list of important factors that may affect future
results is not exhaustive.
When relying on SCT's forward-looking statements to make
decisions with respect to SCT, investors and others should
carefully consider the foregoing factors and other uncertainties
and potential events. Such forward-looking statements are based on
a number of estimates and assumptions which may prove to be
incorrect, including, but not limited to, assumptions regarding the
availability of financing for research and development companies in
addition to general business and economic conditions. These risks
and uncertainties should be considered carefully and investors and
others should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
this press release are based upon what management believes to be
reasonable assumptions, SCT cannot provide assurance that actual
results will be consistent with these forward-looking statements.
SCT undertakes no obligation to update or revise any
forward-looking statement.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp David Allan Executive
Chairman DAllan@StemCellThera.com www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024